For research use only. Not for therapeutic Use.
C12-Ceramide (N-Lauroyl-D-erythro-sphingosine), a naturally occurring ceramide, is formed by hydrolysis of C12 sphingomyelin. C12-Ceramide can enhance the Doxorubicin toxicity in MDA-MB-231 cells. C12-Ceramide also can be used to diagnose types A and B Niemann-Pick disease[1][1].
C12-Ceramide (1 μM; 24-72 h) enhances the liposomal Doxorubicin toxicity in MDA-MB-231 cells[1].
| Catalog Number | R055339 |
| CAS Number | 74713-60-3 |
| Synonyms | N-[(E,2S,3R)-1,3-dihydroxyoctadec-4-en-2-yl]dodecanamide |
| Molecular Formula | C30H59NO3 |
| Purity | ≥95% |
| InChI | InChI=1S/C30H59NO3/c1-3-5-7-9-11-13-14-15-16-18-19-21-23-25-29(33)28(27-32)31-30(34)26-24-22-20-17-12-10-8-6-4-2/h23,25,28-29,32-33H,3-22,24,26-27H2,1-2H3,(H,31,34)/b25-23+/t28-,29+/m0/s1 |
| InChIKey | HXFPPRPLRSPNIB-VARSQMIESA-N |
| SMILES | CCCCCCCCCCCCCC=CC(C(CO)NC(=O)CCCCCCCCCCC)O |
| Reference | [1]. He X, et, al. A fluorescence-based, high-performance liquid chromatographic assay to determine acid sphingomyelinase activity and diagnose types A and B Niemann-Pick disease. Anal Biochem. 2003 Mar 1;314(1):116-20. [2]. Øverbye A, et, al. Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide. Oncotarget. 2017 Aug 12;8(44):76921-76934. |
